drugset / Trial / NCT04555486
Study to Evaluate Safety, Tolerability, PK and PD of DCR-PHXC in PH Type 3 Patients
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The DCR-PHXC-104 study is designed to assess the safety, tolerability, and pharmacological parameters of a single dose of DCR-PHXC in Primary Hyperoxaluria Type 3 (PH3). Participants should have had at least one stone event within 12 months of screening and intact renal function.
Timeline
- Start
- 2020-09-14
- Primary completion
- 2021-09-07
- Completion
- 2021-09-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | DCR-PHXC | Unknown | 3 mg/kg | Subcutaneous |
| Subject | DCR-PHXC | Unknown | 3.5 mg/kg | Subcutaneous |